p38 MAP kinase inhibitors (Triad/Novartis)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namep38 MAP kinase inhibitors (Triad/Novartis)
Drug Alias Nameinflammation therapy (Triad/Novartis)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 α mitogen-activated protein kinase inhibitors
TargetsP38 α mitogen-activated protein kinase
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryWorld
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTriad Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Ag
Active IndicationsN/A
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A